Janet R Vos
Overview
Explore the profile of Janet R Vos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Drissen M, Vos J, Collado Camps E, Schuurs-Hoeijmakers J, Schieving J, Hoogerbrugge N
Eur J Med Genet
. 2024 Jul;
70:104960.
PMID: 39025258
There are indications for immune dysregulation in PTEN Hamartoma Tumour Syndrome (PHTS), however information on the clinical immune phenotype is lacking. We aimed to assess the frequency of infections and...
2.
Elze L, van der Post R, Vos J, Mensenkamp A, Pamidimarri Naga S, Hampstead J, et al.
J Natl Cancer Inst
. 2024 Jul;
116(12):1904-1913.
PMID: 38960732
Background: Individuals with germline pathogenic variants in BRCA1 or BRCA2 are at a high risk of breast and ovarian carcinomas with BRCA1/2 deficiency and homologous recombination deficiency that can be...
3.
Schei-Andersen A, Hendricks L, van der Post R, Mensenkamp A, Schieving J, Schuurs-Hoeijmakers J, et al.
Int J Cancer
. 2024 Jun;
155(9):1567-1576.
PMID: 38861330
PTEN hamartoma tumor syndrome (PHTS) has a broad clinical spectrum including various benign and malignant tumors at varying age of diagnosis. Many patients remain unrecognized, unaware of their increased cancer...
4.
Schei-Andersen A, van Oirschot B, Drissen M, Schieving J, Schuurs-Hoeijmakers J, Vos J, et al.
Int Dent J
. 2024 May;
74(6):1424-1431.
PMID: 38697906
Aims: Patients with PTEN hamartoma tumour syndrome (PHTS) have an increased risk of developing cancer due to a pathogenic germline variant in the PTEN tumour suppressor gene. Early recognition of...
5.
Hendricks L, Verbeek K, Schuurs-Hoeijmakers J, Mensenkamp A, Brems H, de Putter R, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473316
Females with PTEN Hamartoma Tumor Syndrome (PHTS) have breast cancer risks up to 76%. This study assessed associations between breast cancer and lifestyle in European female adult PHTS patients. Data...
6.
Hinic S, Cybulski C, van der Post R, Vos J, Schuurs-Hoeijmakers J, Brugnoletti F, et al.
Genet Med
. 2024 Feb;
26(5):101101.
PMID: 38362852
Purpose: Females with biallelic CHEK2 germline pathogenic variants (gPVs) more often develop multiple breast cancers than individuals with monoallelic CHEK2 gPVs. This study is aimed at expanding the knowledge on...
7.
Drissen M, Vos J, Netea-Maier R, Gotthardt M, Hoogerbrugge N
Endocr Relat Cancer
. 2023 Jul;
30(10).
PMID: 37451289
Thyroid cancer surveillance (TCS) with ultrasound (US) is advised for PTEN hamartoma tumour syndrome (PHTS) patients due to increased thyroid cancer (TC) risk. However, data supporting TCS guidelines are scarce....
8.
Witjes V, Ligtenberg M, Vos J, Braspenning J, Ausems M, Mourits M, et al.
Gynecol Oncol
. 2023 May;
174:121-128.
PMID: 37182432
Objective: Genetic testing in epithelial ovarian cancer (OC) is essential to identify a hereditary cause like a germline BRCA1/2 pathogenic variant (PV). An efficient strategy for genetic testing in OC...
9.
Kwinten K, Drissen M, de Hullu J, Vos J, Hoogerbrugge N, Van Altena A
Eur J Med Genet
. 2023 May;
66(7):104785.
PMID: 37172779
Objective: Expert-opinion based guidelines state that endometrial cancer surveillance (ECS) might be considered for patients with PTEN Hamartoma Tumor Syndrome (PHTS) based on an elevated lifetime risk of endometrial cancer....
10.
Elze L, van der Post R, Vos J, Mensenkamp A, de Hullu M, Nagtegaal I, et al.
J Natl Cancer Inst
. 2023 Apr;
115(7):853-860.
PMID: 37018159
Background: Individuals with Lynch syndrome are at increased hereditary risk of colorectal and endometrial carcinomas with microsatellite instability (MSI-H) and mismatch repair-deficiency (dMMR), which make these tumors vulnerable to therapy...